These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28744395)

  • 1. A bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model.
    Gvozdenovic A; Boro A; Born W; Muff R; Fuchs B
    Am J Cancer Res; 2017; 7(7):1435-1449. PubMed ID: 28744395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
    Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
    MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
    Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
    Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
    Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
    Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
    Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
    Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
    Knowlden JM; Hutcheson IR; Barrow D; Gee JM; Nicholson RI
    Endocrinology; 2005 Nov; 146(11):4609-18. PubMed ID: 16037379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
    Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
    BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.
    Shen Y; Zeng L; Novosyadlyy R; Forest A; Zhu A; Korytko A; Zhang H; Eastman SW; Topper M; Hindi S; Covino N; Persaud K; Kang Y; Burtrum D; Surguladze D; Prewett M; Chintharlapalli S; Wroblewski VJ; Shen J; Balderes P; Zhu Z; Snavely M; Ludwig DL
    MAbs; 2015; 7(5):931-45. PubMed ID: 26073904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts.
    Goetsch L; Gonzalez A; Leger O; Beck A; Pauwels PJ; Haeuw JF; Corvaia N
    Int J Cancer; 2005 Jan; 113(2):316-28. PubMed ID: 15386423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells.
    Song RX; Zhang Z; Chen Y; Bao Y; Santen RJ
    Endocrinology; 2007 Aug; 148(8):4091-101. PubMed ID: 17525128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
    Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
    Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
    Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
    Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.
    Avnet S; Sciacca L; Salerno M; Gancitano G; Cassarino MF; Longhi A; Zakikhani M; Carboni JM; Gottardis M; Giunti A; Pollak M; Vigneri R; Baldini N
    Cancer Res; 2009 Mar; 69(6):2443-52. PubMed ID: 19258511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.